By comparison, prostate cancer figures are somewhat better, with about one-third of patients surviving beyond two years. Elsewhere in the world, these figures are nearly 100 per cent for prostate ...
Scientists at UC San Francisco have developed a revolutionary cancer treatment that precisely targets tumors with radiation ...
Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™)
Samsung Bioepis Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for OBODENCE™ (60mg pre-filled syringe ...
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback